SEPREHVIR®
VIRTTU's lead product SEPREHVIR® (HSV1716) is a "first in class" engineered oncolytic herpes simplex virus designed to selectively target and destroy cancerous cells whilst leaving healthy cells unharmed.
We have completed Phase I clinical trials with HSV1716 in 47 patients with glioma (in 3 trials), in 5 patients with melanoma, and in 20 patients with squamous cell carcinoma of the head and neck.
There has been no observed toxicity attributable to the use of HSV1716 in any of these clinical studies. Our intention is to follow through with an efficacy study of SEPREHVIR® (HSV1716) in a randomised controlled clinical study in newly diagnosed glioblastoma multiforme.
Further clinical studies are planned as part of our goal to identify effective treatments for a range of other cancers including hepatocelllular carcinoma and mesothelioma.
In May 2010 the first clinical study in the US commenced at Cincinnati Children's Hospital Medical Center. The study is investigating the use of HSV1716 in paediatric/young adults with non-central nervous system tumours including sarcomas or neuroblastomas.
Products in clinical development
| Product | Indication | Research & Pre-clinical | Phase I | Phase II | Phase III | Status |
|---|---|---|---|---|---|---|
|
SEPREHVIR® (HSV1716) |
Malignant brain tumours | Completed | 3x Ph I Completed | In preparation |
Orphan Drug Status (EMA) Study in primary GBM planned |
|
|
SEPREHVIR® (HSV1716) |
Squamous cell carcinoma of head and neck | Completed | Ph I Completed | Phase I trial completed | ||
|
SEPREHVIR® (HSV1716) |
Malignant melanoma | Completed | Ph I Completed | Phase I trial completed | ||
|
SEPREHVIR® (HSV1716) |
Hepatocellular carcinoma | Completed | In Preparation | Due to commence Q4 2011 | ||
|
SEPREHVIR® (HSV1716) |
Malignant pleural mesothelioma | Completed | In Preparation | Due to commence Q4 2011 | ||
|
SEPREHVIR® (HSV1716) |
Paediatric and young adults with Non-CNS solid tumours (eg neuroblastoma or sarcoma) | Completed | Ongoing |
Recruiting at Cincinnati Children's Hospital Medical Center |
Products
VIRTTU's lead product SEPREHVIR®, a "First in Class" oncolytic virus, shows broad utility against a range of difficult to treat cancers.
Advice and Support for Patients
If you are suffering from any form of cancer or know anyone that is, click here for links to organisations that offer advice and support.